Respiratory Syncytial Virus or RSV is one of the most common respiratory viruses circulating today. Often thought of as only being dangerous to babies and toddlers due to how often child-related ...

Last winter’s respiratory syncytial virus, or RSV, season wasn’t as brutal for U.S. babies. A new study suggests two preventive tools — a maternal vaccine and a monoclonal antibody for ...

Respiratory syncytial virus (RSV)–associated hospitalization rates among infants in the United States were significantly lower in the first year when prevention products were widely available ...

RSV prevention products led to a significant reduction in hospitalization rates for infants aged 0 to 7 months during the 2024-2025 season. The maternal RSV vaccine and nirsevimab were key ...

But a rise in hospitalizations among slightly older children — still at risk but too old to be eligible for the products — shows the decline occurred in the context of a severe RSV season.

Babies treated with nirsevimab had an 83% reduced risk of hospitalization due to RSV infection, researchers reported May 1 in The Lancet Child & Adolescent Health. The antibody treatment also ...

Among 69 hospitalisations of infants for respiratory syncytial virus (RSV)–related lower respiratory tract infection (LRTI) in a Spanish study, 65.2% occurred despite the administration of ...

The panel voted 14-0 to recommend a single shot of both RSV vaccines for adults aged 50-59 who are at increased risk of RSV-associated lower respiratory tract disease. The shots are currently ...

Nirsevimab associated with lower odds of RSV-related hospitalization, ICU admission, lower respiratory tract infection incidence. HealthDay News — Nirsevimab is effective for reducing the burden ...

AstraZeneca and Sanofi have secured approval in the EU for Beyfortus, the first single-dose drug to protect newborns and infants from respiratory syncytial virus (RSV) infections. The antibody ...